[go: up one dir, main page]

PE20001495A1 - Derivados de mevinolina - Google Patents

Derivados de mevinolina

Info

Publication number
PE20001495A1
PE20001495A1 PE2000000114A PE0001142000A PE20001495A1 PE 20001495 A1 PE20001495 A1 PE 20001495A1 PE 2000000114 A PE2000000114 A PE 2000000114A PE 0001142000 A PE0001142000 A PE 0001142000A PE 20001495 A1 PE20001495 A1 PE 20001495A1
Authority
PE
Peru
Prior art keywords
alkyl
alcoxyl
mevinoline
derivatives
hydroxyalkyl
Prior art date
Application number
PE2000000114A
Other languages
English (en)
Inventor
Sylvain Cottens
Wilfried Bauer
Gabriele Weitz-Schmidt
Joerg Kallen
Ulrich Hommel
Rolf Baenteli
Claus Ehrhardt
Josef Gottfried Meingassner
Francois Nuninger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9903546A external-priority patent/GB9903546D0/en
Priority claimed from GB9927880A external-priority patent/GB9927880D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20001495A1 publication Critical patent/PE20001495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

SE REFIERE A DERIVADOS DE MEVINOLINA DE FORMULA I, DONDE R1 ES H, ALQUILO C1-C4, ORa; Ra ES H, ALQUILO C1-C6; R2 ES OCOR5; R5 ES ALQUILO C1-C8, CICLOALQUILO C3-C7, OR6, ENTRE OTROS; R6 ES UN O-AMINOACIDO UNIDO A O POR UN CARBONILO, HR7C-COR8; R7 ES H, ALQUILO C1-C4, HETEROALQUILO C1-C4, ENTRE OTROS; R8 ES OH, ALCOXILO C1-C4, NR9R10; R9 Y R10 SON H, ALQUILO C1-C4 O JUNTO CON N FORMAN UN HETEROARILO; R3 ES UNA LACTAMA, PIPERIDILO, AMINO-ALCOHOL, CARBAMATO CICLICO, -CH2-CH(R13)-CH2-CH(R14)-CHR15R16; R13 ES OH, ALCOXILO C1-C6, -O-CO-ALQUILO C1-C6, OCONH-ALQUILO C1-C6; R14 ES OH, ALCOXILO C1-C4, ALQUILO C1-C4, ENTRE OTROS; R15 ES H, ALQUILO C1-C4; R16 ES CONR17R8; UNO DE R17 Y R18 ES H Y EL OTRO ES ALQUILO C1-C6, HIDROXIALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS; R4 ES H, OR19; R19 ES ALQUILO C1-C6, HIDROXIALQUILO C1-C6, ALCOXILO C1-C4, ENTRE OTROS. UN COMPUESTO PREFERIDO ES (S)-(3R,8aR)-8-{(S)-2-[(1R,5R)-3-(4-HIDROXI-3-METOXI-BENCIL)-4-METILCARBAMOILMETIL-2-OXO[1,3]OXAZINAN-6-IL]-ETIL}-7-METIL-3-METIL-1,2,3,7,8,8a-HEXAHIDRO-NAFTALEN-1-ILESTER DE ACIDO (S)-2-METILBUTIRICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS UN INMUNOSUPRESOR, INMUNOMODULADOR, ANTIINFLAMATORIO. EL COMPUESTO I ES UN INHIBIDOR DE LA ADHESION DEL ANTIGENO LFA-1 A LA MOLECULA 1 DE ADHESION INTERCELULAR ICAM-1
PE2000000114A 1999-02-16 2000-02-14 Derivados de mevinolina PE20001495A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9903546A GB9903546D0 (en) 1999-02-16 1999-02-16 Organic compounds
GB9927880A GB9927880D0 (en) 1999-11-25 1999-11-25 Organic compounds

Publications (1)

Publication Number Publication Date
PE20001495A1 true PE20001495A1 (es) 2001-01-12

Family

ID=26315146

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000114A PE20001495A1 (es) 1999-02-16 2000-02-14 Derivados de mevinolina

Country Status (17)

Country Link
US (2) US20020037895A1 (es)
EP (1) EP1154988B1 (es)
JP (1) JP4167806B2 (es)
CN (1) CN1229335C (es)
AR (1) AR022588A1 (es)
AT (1) ATE273272T1 (es)
AU (1) AU763357B2 (es)
BR (1) BR0008292A (es)
CA (1) CA2361841C (es)
CO (1) CO5140104A1 (es)
DE (1) DE60012888T2 (es)
DK (1) DK1154988T3 (es)
ES (1) ES2226802T3 (es)
PE (1) PE20001495A1 (es)
PT (1) PT1154988E (es)
SI (1) SI1154988T1 (es)
WO (1) WO2000048989A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2758037B2 (ja) * 1989-08-04 1998-05-25 株式会社アマダ タレットパンチプレスの金型インデックス装置
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6878700B1 (en) 1998-12-29 2005-04-12 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6110922A (en) 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
CA2414461A1 (en) 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
JP2004512278A (ja) * 2000-09-19 2004-04-22 ノビムーヌ　ソシエテ　アノニム 新規な免疫調節剤、免疫阻害剤、及び抗炎症剤としてのスタチン（ＨＭＧ−ＣｏＡリダクターゼ阻害剤）
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
AU2003282510A1 (en) 2002-10-11 2004-05-04 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
EP1702910A4 (en) * 2003-12-26 2007-11-07 Nippon Shinyaku Co Ltd OCTAHYDRONAPHTHALENE DERIVATIVES AND DRUG
US7396530B2 (en) * 2004-06-09 2008-07-08 Genentech, Inc. Method of treating granuloma annulare or sarcoid
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
TW200616634A (en) 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US7186727B2 (en) 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
CN101873797A (zh) 2007-10-19 2010-10-27 萨可德公司 用于治疗糖尿病性视网膜病的组合物和方法
CN102617533B (zh) * 2011-02-01 2014-08-27 北京北大维信生物科技有限公司 一种从红曲中分离的化合物、其制备方法及用途
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
WO2017038650A1 (ja) * 2015-08-28 2017-03-09 積水メディカル株式会社 ベンジル化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678806A (en) 1986-09-02 1987-07-07 Merck & Co., Inc. Prodrugs of antihypercholesterolemic compounds
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
EP0415488B1 (en) * 1989-08-31 1994-04-20 Merck & Co. Inc. 7-Substituted HMG-COA reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
US5393893A (en) 1993-11-08 1995-02-28 Apotex, Inc. Process for producing simvastatin and analogs thereof
JPH11515025A (ja) * 1995-11-02 1999-12-21 ワーナー−ランバート・コンパニー 脂質濃度を調節するための方法および医薬組成物
US5763653A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Key intermediates in the manufacture of simvastatin
US5763646A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid
DE69813538T2 (de) 1997-01-28 2004-04-01 Plus Chemicals B.V. Verfahren zur herstellung von halbsynthetischen statinen vianeue zwischenprodukte
PT1007033E (pt) * 1997-08-28 2008-07-22 Novartis Ag Antagonistas do antigénio-1 da função de linfócitos

Also Published As

Publication number Publication date
EP1154988B1 (en) 2004-08-11
CN1340044A (zh) 2002-03-13
DE60012888T2 (de) 2005-08-18
JP4167806B2 (ja) 2008-10-22
AR022588A1 (es) 2002-09-04
ES2226802T3 (es) 2005-04-01
JP2002537284A (ja) 2002-11-05
SI1154988T1 (en) 2005-02-28
BR0008292A (pt) 2001-11-06
US20030087903A1 (en) 2003-05-08
PT1154988E (pt) 2004-12-31
AU763357B2 (en) 2003-07-17
DK1154988T3 (da) 2004-11-22
US20020037895A1 (en) 2002-03-28
AU3804000A (en) 2000-09-04
WO2000048989A1 (en) 2000-08-24
CA2361841C (en) 2008-12-02
US6818638B2 (en) 2004-11-16
CA2361841A1 (en) 2000-08-24
ATE273272T1 (de) 2004-08-15
DE60012888D1 (de) 2004-09-16
EP1154988A1 (en) 2001-11-21
CN1229335C (zh) 2005-11-30
CO5140104A1 (es) 2002-03-22

Similar Documents

Publication Publication Date Title
PE20001495A1 (es) Derivados de mevinolina
PE20050729A1 (es) Aminas ciclicas sustituidas por bezamida o piridin-carboxamida como inhibidores de bace-1
AR034244A1 (es) Derivados de 4-aminopiperidina y su uso como medicamento
PE20020707A1 (es) Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
CO5690561A2 (es) Administracion oral de acido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil]fosfonico y derivados
HUP0303037A2 (hu) Alzheimer-kór kezelésére alkalmas vegyületek és ezeket tartalmazó gyógyszerkészítmények
MY133992A (en) Muscarinic antagonists
NO175259C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive triazolo-1,4-diazepinforbindelser
NZ233970A (en) N-heteroaryl-purin-6-amines and pharmaceutical compositions
KR920703628A (ko) 티로트로핀-방출 호르몬(trh)의 프로드러그 유도체
BR0309558A (pt) Derivados de quinazolina e medicamentos
MX9504800A (es) Derivados de acido nipecotico como compuestos antitromboticos.
PE20020294A1 (es) Derivados de pirrolidina como inhibidores de la enzima conversor de endotelina
UA41928C2 (uk) Похідні оксазолідину, спосіб їх одержання, фармацевтична композиція та спосіб її одержання, спосіб лікування захворювань
KR900014388A (ko) 에세롤린의 카보네이트 유도체, 이의 제조방법 및 약제로서의 용도
PE20050050A1 (es) Derivados de indolilo
PE20020426A1 (es) ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
ATE226934T1 (de) Ester und amide als pla2-inhibitoren
DK0599240T3 (da) Indol-7-carboxamidderivater som analgetika
AR027578A1 (es) Derivados de indano
CA2072416A1 (en) Cyclopropenone derivatives
ATE12933T1 (de) N-substituierte azaheterocyclische carbonsaeure und ihre ester.
FR2631339B1 (fr) Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique
DE69132707D1 (de) N-Acyldipeptide, und pharmazeutische Präparate davon

Legal Events

Date Code Title Description
FC Refusal